#ASH22: No­var­tis PNH drug tops As­traZeneca with what's de­scribed as 'prac­tice-chang­ing' po­ten­tial

NEW OR­LEANS — No­var­tis showed hema­tol­o­gists and in­dus­try in­sid­ers Tues­day morn­ing just how well ip­ta­co­pan beat As­traZeneca’s two stan­dard-of-care med­i­cines for a rare blood dis­ease – nail­ing both pri­ma­ry end­points, while ze­ro pa­tients on Soliris and Ul­tomiris achieved ei­ther.

The Swiss Big Phar­ma and its tri­al in­ves­ti­ga­tors pre­sent­ed the fleshed-out da­ta in a late-break­er at the an­nu­al Amer­i­can So­ci­ety of Hema­tol­ogy con­fer­ence, show­ing that pa­tients on the drug had a sub­stan­tial in­crease in their he­mo­glo­bin lev­els from their start­ing point and al­so reached a nor­mal base­line.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER